Table 1. Baseline Characteristics by Medication Cohort for Optum Clinformatics Data Mart and Truven MarketScan.
Variable | No. (%) | |||||||
---|---|---|---|---|---|---|---|---|
Reference Group: MTX Users (Compared With Adalimumab)a | Adalimumab Users | Acitretin Users | Apremilast Users | Etanercept Users | Infliximab Users | Ustekinumab Users | Total Across Medications | |
Optum | ||||||||
Patients, y, No. | 8470 | 7181 | 2726 | 1623 | 7102 | 408 | 4085 | 31 595 |
Age, y | ||||||||
Mean (SD) | 53.69 (15.48) | 46.10 (12.97) | 52.31 (13.89) | 51.37 (13.77) | 45.45 (12.99) | 50.20 (14.59) | 46.50 (12.84) | NAb |
Categories | ||||||||
18-54 | 4387 (51.8) | 5255 (73.2) | 1506 (55.2) | 944 (58.2) | 5332 (75.1) | 253 (62.0) | 2974 (72.8) | 20 651 (65.4) |
55-64 | 1892 (22.3) | 1389 (19.3) | 759 (27.8) | 417 (25.7) | 1304 (18.4) | 85 (20.8) | 815 (20.0) | 6661 (22.1) |
65-74 | 1484 (17.5) | 449 (6.3) | 324 (11.9) | 201 (12.4) | 372 (5.2) | 49 (12.0) | 236 (5.8) | 3115 (9.9) |
≥75 | 707 (8.3) | 88 (1.2) | 137 (5.0) | 61 (3.8) | 94 (1.3) | 21 (5.1) | 60 (1.5) | 1168 (3.7) |
Sex | ||||||||
Male | 4043 (47.7) | 4061 (56.6) | 1582 (58.0) | 820 (50.5) | 3903 (55.0) | 202 (49.5) | 2302 (56.4) | 16 913 (53.5) |
Female | 4426 (52.3) | 3120 (43.4) | 1144 (42.0) | 803 (49.5) | 3199 (45.0) | 206 (50.5) | 1781 (43.6) | 14 679 (46.5) |
Unknown | 1 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.0) | 3 (0.0) |
Obese | 526 (6.2) | 372 (5.2) | 137 (5.0) | 87 (5.4) | 336 (4.7) | 27 (6.6) | 251 (6.1) | 1736 (5.5) |
Smokers | 477 (5.6) | 326 (4.5) | 148 (5.4) | 57 (3.5) | 332 (4.7) | 24 (5.9) | 184 (4.5) | 1548 (4.9) |
Depression | 191 (2.3) | 178 (2.5) | 45 (1.7) | 27 (1.7) | 176 (2.5) | 13 (3.2) | 76 (1.9) | 706 (2.2) |
Combined comorbidity score, mean (SD) | 0.14 (1.03) | 0.07 (0.79) | 0.14 (1.08) | 0.14 (0.85) | 0.07 (0.81) | 0.23 (1.13) | 0.08 (0.78) | NAb |
Region | ||||||||
Northeast | 771 (9.1) | 602 (8.4) | 305 (11.2) | 209 (12.9) | 662 (9.3) | 34 (8.3) | 423 (10.4) | 3006 (9.5) |
Midwest | 2140 (25.3) | 1771 (24.7) | 582 (21.3) | 380 (23.4) | 1659 (23.4) | 137 (33.6) | 975 (23.9) | 7644 (24.2) |
South | 3719 (43.9) | 3726 (51.9) | 1388 (50.9) | 706 (43.5) | 3708 (52.2) | 195 (47.8) | 2027 (49.6) | 15 469 (49.0) |
West | 1813 (21.4) | 1075 (15.0) | 447 (16.4) | 326 (20.1) | 1064 (15.0) | 42 (10.3) | 656 (16.1) | 5423 (17.2) |
Other | 27 (0.3) | 7 (0.1) | 4 (0.1) | 2 (0.1) | 9 (0.1) | 0 (0.0) | 4 (0.1) | 53 (0.17) |
Commercial/Medicare | ||||||||
Commercial | 6304 (74.4) | 6740 (93.9) | 2371 (87.0) | 1389 (85.6) | 6720 (94.6) | 351 (86.0) | 3807 (93.2) | 27 682 (87.6) |
Medicare | 2166 (25.6) | 441 (6.1) | 355 (13.0) | 234 (14.4) | 382 (5.4) | 57 (14.0) | 278 (6.8) | 3913 (12.4) |
Nursing home resident | 33 (0.4) | 4 (0.1) | 8 (0.3) | 4 (0.2) | 4 (0.1) | 3 (0.7) | 6 (0.1) | 62 (0.2) |
≥1 Outpatient office visit | 8155 (96.3) | 7065 (98.4) | 2658 (97.5) | 1605 (98.9) | 6961 (98.0) | 402 (98.5) | 4026 (98.6) | 30 872 (97.7) |
≥1 Emergency department visit | 806 (9.5) | 551 (7.7) | 236 (8.7) | 131 (8.1) | 482 (6.8) | 45 (11.0) | 314 (7.7) | 2565 (8.1) |
≥1 Inpatient hospitalization | 416 (4.9) | 241 (3.4) | 125 (4.6) | 63 (3.9) | 315 (4.4) | 32 (7.8) | 115 (2.8) | 1307 (4.1) |
≥1 Laboratory test | 6473 (76.4) | 5794 (80.7) | 2045 (75.0) | 1142 (70.4) | 5457 (76.8) | 364 (89.2) | 3244 (79.4) | 24 519 (77.6) |
Truven MarketScan | ||||||||
Patients, No. | 20 609 | 17 912 | 7456 | 4476 | 16 791 | 1027 | 7841 | 76 112 |
Age, y | ||||||||
Mean (SD) | 50.62 (13.82) | 46.20 (12.89) | 53.00 (12.99) | 50.52 (12.84) | 46.65 (13.27) | 48.18 (12.47) | 46.89 (12.86) | NAb |
Categories | ||||||||
18-54 | 12 100 (58.7) | 12 848 (71.7) | 3822 (51.3) | 2631 (58.8) | 11 790 (70.2) | 691 (67.3) | 5502 (70.2) | 49 384 (64.9) |
55-64 | 5819 (28.2) | 4064 (22.7) | 2505 (33.6) | 1373 (30.7) | 3800 (22.6) | 252 (24.5) | 1821 (23.2) | 19 634 (25.8) |
65-74 | 1791 (8.7) | 767 (4.3) | 773 (10.4) | 359 (8.0) | 894 (5.3) | 62 (6.0) | 404 (5.2) | 5050 (6.6) |
≥75 | 899 (4.4) | 233 (1.3) | 356 (4.8) | 113 (2.5) | 307 (1.8) | 22 (2.1) | 114 (1.5) | 2044 (2.7) |
Sex | ||||||||
Male | 9604 (46.6) | 9903 (55.3) | 4222 (56.6) | 2176 (48.6) | 9101 (54.2) | 474 (46.2) | 4303 (54.9) | 39 783 (52.3) |
Female | 11 005 (53.4) | 8009 (44.7) | 3234 (43.4) | 2300 (51.4) | 7690 (45.8) | 553 (53.8) | 3538 (45.1) | 36 329 (47.7) |
Obese | 843 (4.1) | 746 (4.2) | 256 (3.4) | 245 (5.5) | 607 (3.6) | 59 (5.7) | 379 (4.8) | 3135 (4.1) |
Smokers | 812 (3.9) | 711 (4.0) | 284 (3.8) | 169 (3.8) | 536 (3.2) | 50 (4.9) | 357 (4.6) | 2919 (3.8) |
Depression | 987 (4.8) | 879 (4.9) | 319 (4.3) | 141 (3.2) | 825 (4.9) | 65 (6.3) | 364 (4.6) | 3580 (4.7) |
Combined comorbidity score, mean (SD) | 0.08 (0.82) | 0.05 (0.72) | 0.08 (0.91) | 0.08 (0.81) | 0.06 (0.72) | 0.18 (1.04) | 0.05 (0.77) | NAb |
Region | ||||||||
Northeast | 3088 (15.0) | 2588 (14.4) | 1323 (17.7) | 994 (22.2) | 2428 (14.5) | 158 (15.4) | 1494 (19.1) | 12 073 (15.9) |
North Central | 4940 (24.0) | 4266 (23.8) | 1611 (21.6) | 986 (22.0) | 4210 (25.1) | 244 (23.8) | 1595 (20.3) | 17 852 (23.5) |
South | 8478 (41.1) | 8210 (45.8) | 3022 (40.5) | 1928 (43.1) | 7251 (43.2) | 531 (51.7) | 3560 (45.4) | 32 980 (43.3) |
West | 3777 (18.3) | 2547 (14.2) | 1420 (19.0) | 554 (12.4) | 2576 (15.3) | 87 (8.5) | 1016 (13.0) | 11 977 (15.7) |
Unknown | 326 (1.6) | 301 (1.7) | 80 (1.1) | 14 (0.3) | 326 (1.9) | 7 (0.7) | 176 (2.2) | 1230 (1.6) |
Commercial/Medicare | ||||||||
Commercial | 17 872 (86.7) | 16 896 (94.3) | 6297 (84.5) | 3995 (89.3) | 15 563 (92.7) | 935 (91.0) | 7299 (93.1) | 68 857 (90.5) |
Medicare | 2737 (13.3) | 1016 (5.7) | 1159 (15.5) | 481 (10.7) | 1228 (7.3) | 92 (9.0) | 542 (6.9) | 7255 (9.5) |
Nursing home resident | 26 (0.1) | 9 (0.1) | 9 (0.1) | 5 (0.1) | 7 (0.0) | 2 (0.2) | 9 (0.1) | 67 (0.1) |
≥1 Outpatient office visit | 19 848 (96.3) | 17 644 (98.5) | 7261 (97.4) | 4427 (98.9) | 16 417 (97.8) | 1018 (99.1) | 7735 (98.6) | 74 350 (97.7) |
≥1 Emergency department visit | 2256 (10.9) | 1721 (9.6) | 717 (9.6) | 473 (10.6) | 1676 (10.0) | 148 (14.4) | 754 (9.6) | 7745 (10.2) |
≥1 Inpatient hospitalization | 886 (4.3) | 636 (3.6) | 334 (4.5) | 192 (4.3) | 706 (4.2) | 69 (6.7) | 259 (3.3) | 3082 (4.0) |
≥1 Laboratory test | 15 896 (77.1) | 15 016 (83.8) | 5465 (73.3) | 3264 (72.9) | 13 033 (77.6) | 907 (88.3) | 6332 (80.8) | 59 913 (78.7) |
Abbreviations: MTX, methotrexate; NA, not available.
Results presented for methotrexate users were obtained from the adalimumab comparative analysis.
Groups were not completely mutually exclusive, and thus a pooled standard deviation could not be calculated for the mean.